An announcement from Zevra Therapeutics ( (ZVRA) ) is now available.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Zevra Therapeutics has announced the commercial availability of MIPLYFFA™ (arimoclomol), the first FDA-approved treatment for Niemann-Pick Disease Type C (NPC). This breakthrough offers a new hope for patients, as it is used in combination with miglustat to treat neurological symptoms in both adults and children. Zevra’s patient support program, AmplifyAssist™, provides essential resources to navigate prescription processes and insurance challenges, ensuring patients can access this life-changing therapy.
See more data about ZVRA stock on TipRanks’ Stock Analysis page.
